A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Umair Mahmood(Dana-Farber Cancer Institute), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Hyung‐Jin Yoo(University of Tennessee Medical Center), Lori J. Wirth(Massachusetts General Hospital), Glenn J. Hanna(Dana-Farber Cancer Institute), Paul M. Busse(Massachusetts General Hospital), Vishwajith Sridharan(Massachusetts General Hospital), Henning Willers(Massachusetts General Hospital), Claire Manuszak(Dana-Farber Cancer Institute), Mariano Severgnini(Dana-Farber Cancer Institute), Sara I. Pai(Yale University), Raymond H. Mak(Twitter (United States)), Mizuki Nishino(Brigham and Women's Hospital), Emily M. Thrash(Dana-Farber Cancer Institute), Roy B. Tishler(Dana-Farber Cancer Institute), Danielle N. Margalit(Harvard University), Matthew R. Sanborn(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Harvey J. Mamon(Brigham and Women's Hospital), Yu‐Hui Chen(Dana-Farber Cancer Institute), Andrew Bang(Dana-Farber Cancer Institute), Nicole G. Chau(University of British Columbia), Jochen H. Lorch(Northwestern University)
International Journal of Radiation Oncology*Biology*Physics
August 8, 2020
Cited by 111
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k